While several studies have suggested NHE1 inhibition as a potential approach to overcome chemoresistance in AML [8,9,10], the underlying mechanisms remain unclear, with different mediators identified across studies, highlighting the complex role of NHE1 in chemoresistance. The gene discussed is SLC9A1; the disease is acute myeloid leukemia.